Both the US Food and Drug Administration and the UK medicines regulator have finalized their groundbreaking approvals of the first CRISPR gene therapy for Casgevy, a therapy built on the CRISPR-Cas9 gene editing tool.
A trend is graded on whether the publisher keeps it, never as a hit or a miss (D6, D33).